The Food and Drug Law Institute
China’s New Drug GMP: Higher Standard, New Compliance Philosophy
November/December 2011
China’s major new drug Good Manufacturing Practices regulations (GMP 2010) took effect on March 1, 2011. Multinational companies can no longer rely solely upon compliance with U.S. or EU GMP regulations, and will need to review current procedures in China.
This article has been reprinted with the permission of FDLI.
Contacts
Capabilities
Suggested News & Insights
U.S. FDA Plans to Increase the Number of Surprise Foreign InspectionsMay 7, 2025Sidley Represented Zylox-Tonbridge in Equity Investment in Avinger, Inc.March 8, 2024Drug Development Models in China and the Impact on Multinational Pharmaceutical CompaniesSeptember / October 2013China Gets Tough on Labeling and Packaging of Medtech ImportsAugust 2012
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory